Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.
L Rhoda Molife
Research Funding - AstraZeneca
Joaquin Mateo
No relevant relationships to disclose
Trevor McGoldrick
No relevant relationships to disclose
Matthew Krebs
No relevant relationships to disclose
Yvette Drew
No relevant relationships to disclose
Susana N. Banerjee
No relevant relationships to disclose
Shibani Nicum
No relevant relationships to disclose
Malcolm Ranson
Consultant or Advisory Role - Safety Review Panel
Gordon J. S. Rustin
Consultant or Advisory Role - AstraZeneca
Cristiana Sessa
No relevant relationships to disclose
Ruth Plummer
No relevant relationships to disclose
Karin Leunen
No relevant relationships to disclose
Michael Friedlander
Consultant or Advisory Role - AstraZeneca
Helen Swaisland
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Wendy Burke
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Peter McCormack
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Kristine Pemberton
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Ilian Tchakov
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Stanley B. Kaye
Consultant or Advisory Role - AstraZeneca; AstraZeneca
Honoraria - AstraZeneca; AstraZeneca
Charlie Gourley
Research Funding - AstraZeneca